Janux Therapeutics, Inc. financial data

Symbol
JANX on Nasdaq
Location
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.82K % +8.13%
Debt-to-equity 4.17 % -32%
Return On Equity -10.2 % +2.68%
Return On Assets -9.78 % +0.81%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.1M shares +14.6%
Common Stock, Shares, Outstanding 60.1M shares +14.9%
Entity Public Float 1.3B USD +365%
Common Stock, Value, Issued 60K USD +15.4%
Weighted Average Number of Shares Outstanding, Basic 62M shares +13.5%
Weighted Average Number of Shares Outstanding, Diluted 62M shares +13.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 115M USD +92.5%
General and Administrative Expense 39.1M USD -0.14%
Operating Income (Loss) -144M USD -67.9%
Nonoperating Income (Expense) 42.4M USD +66.7%
Net Income (Loss) Attributable to Parent -102M USD -68.3%
Earnings Per Share, Basic -1 USD/shares -46.1%
Earnings Per Share, Diluted -1 USD/shares -46.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.4M USD +80.9%
Accounts Receivable, after Allowance for Credit Loss, Current 7.5M USD
Assets, Current 998M USD +49.8%
Property, Plant and Equipment, Net 4.31M USD -19.7%
Operating Lease, Right-of-Use Asset 18.9M USD -3.88%
Other Assets, Noncurrent 2.63M USD -6.94%
Assets 1.02B USD +47.4%
Accounts Payable, Current 3.4M USD +37.9%
Employee-related Liabilities, Current 4.03M USD +3.36%
Accrued Liabilities, Current 22.2M USD +70.1%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 27.8M USD +62.1%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 20.4M USD -6.26%
Liabilities 48.2M USD +23.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.56M USD -41.7%
Retained Earnings (Accumulated Deficit) -319M USD -46.8%
Stockholders' Equity Attributable to Parent 977M USD +48.8%
Liabilities and Equity 1.02B USD +47.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17M USD -14.7%
Net Cash Provided by (Used in) Financing Activities 554K USD -99.8%
Net Cash Provided by (Used in) Investing Activities -340M USD -199%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 60.1M shares +14.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 66.7M USD +48.4%
Deferred Tax Assets, Gross 73.4M USD +39.5%
Operating Lease, Liability 22.7M USD -3.29%
Depreciation 519K USD -2.44%
Payments to Acquire Property, Plant, and Equipment 371K USD +88.3%
Lessee, Operating Lease, Liability, to be Paid 29.9M USD -7.63%
Property, Plant and Equipment, Gross 10.8M USD +10.2%
Operating Lease, Liability, Current 2.28M USD +35%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.17M USD +15.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.05M USD +15.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.27M USD -19%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.87M USD +4.01%
Deferred Tax Assets, Operating Loss Carryforwards 25.7M USD +37%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.03M USD +68.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.95M USD +3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 6.66M USD -12.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%